



MAIL STOP - AMENDMENT  
Docket No. 27230U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: FUCHSS Art Unit: 1625  
Appl. No.: 10/573,203 Examiner: Rahmani, N.  
Filing Date: March 24, 2006 Conf. No.: 1948  
Title: **IMIDAZO (4,5-B) PYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS**

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

A Second Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

a. ☐ The enclosed second statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

b. ☒ [XXX] The enclosed second statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed second statement is accompanied by [check one]:

- ☐ i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or  
☒ ii. a check in the amount required by 37 C.F.R. 1.17(p).

c. ☐ The enclosed second statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee. 180.00 0P  
☐ Certification report(e) below; and  
☐ a check in the amount as required by 1.17(p).

- d. ☐ The enclosed second statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.
- e. Certification ☐ [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]  
☐ I hereby certify that each item of information contained in the enclosed second Information Disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this second statement,  
or  
☐ I hereby certify that no item of information in the enclosed second Information Disclosure statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this second Information Disclosure statement.  
or  
☐ Appropriate certification is attached.
- f. ☒ If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.
- g. ☒ Copies of the documents are attached herewith with a completed PTO Form-1449.  
or  
☐ Copies of the documents are not attached, with a completed PTO Form-1449 as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:  
and / or  
☒ Copies of US Patents/Publications not attached, with a completed PTO Form-1449 as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the


**MAIL STOP - AMENDMENT**

**Docket No. 27230U**

space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,  
**THE NATH LAW GROUP**

By:   
Gary M. Nath  
Registration No. 26,965  
Joshua B. Goldberg  
Registration No. 44,126  
Sheldon M. McGee  
Registration No. 50,454  
Customer No. 34375

Date: August 7, 2007  
**THE NATH LAW GROUP**  
112 South West Street  
Alexandria, VA 22314  
(703)-548-6284



<b>SECOND PTO FORM-1449</b>  <b>INFORMATION DISCLOSURE</b> <b>CITATION</b>		Inventor: FUCHSS		Art Unit: 1625	
		Appl. No.: 10/573,203		Examiner: Rahmani, N.	
		Filing Date: 3/24/2006		Conf. No: 1948	
<b>U.S. PATENT DOCUMENTS</b>					
Exam. Initial		Document No.	Issue/Public. Date	Inventor	Filed Date
	A1	7,138,399 (corresponds to WO03/080607)	11/21/2006	Ulrich	3/25/2003
<b>FOREIGN PATENT DOCUMENTS</b>					
Exam. Initial		Document No.	Public. Date	Country	Translation
	A2	2005/030769 A1	4/7/2005	WO	N/A
	A3	2005/030771 A1	4/7/2005	WO	N/A
	A4	2005/030770 A1	4/7/2005	WO	N/A
	A5	2005/061496 A1	7/7/2005	WO	N/A
	A6	97/25030 A1	7/17/1997	WO	N/A
	A7	03/080607 A1	10/2/2003	WO	N/A
<b>OTHER</b>					
Exam. Initial					
	A8	Hua, L.L., et al., "Role of mitogen-activated protein kinases in inducible nitric oxide synthase and TNF $\alpha$ expression in human fetal astrocytes", <u>Journal of Neuroimmunology</u> , Vol. 126, Pgs. 180-189, (2002).			
	A9	Kim, M-S, et al., "Water-soluble chitosan inhibits the production of pro-inflammatory cytokine in human astrocytoma cells activated by amyloid $\beta$ peptide and interleukin-1 $\beta$ ", <u>Neuroscience Letters</u> , Vol. 321, Pgs. 105-109, (2002).			
	A10	Sautebin, L., "Prostaglandins and nitric oxide as molecular targets for anti-inflammatory therapy", <u>Fitoterapia</u> , Vol. 71, Pgs. S48-S57, (2000).			

A11	Ohtsuka, M., et al., "PPA250 [3-(2,4-Difluorophenyl)-6-{2-[4-(1H-imidazol-1-ylmethyl)Phenoxy]ethoxy}-2-phenylpyridine], a Novel Orally Effective Inhibitor of the Dimerization of Inducible Nitric-Oxide Synthase, Exhibits an Anti-Inflammatory Effect in Animal Models of Chronic Arthritis", <u>The Journal of Pharmacology and Experimental Therapeutics</u> , Vol. 303, No. 1, Pgs. 52-57, (2002).
A12	Hansel, T. T., et al., "A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics", <u>FASEB J</u> , Vol. 17, Pgs. 1298-1300, (2003).
A13	Tinker, A. C., et al., "1,2-Dihydro-4-quinazolinamines: Potent, Highly Selective Inhibitors of Inducible Nitric Oxide Synthase Which Show Antiinflammatory Activity in Vivo", <u>J. Med. Chem.</u> , Vol. 46, Pgs. 913-916, (2003).
A14	Kankuri, E., et al., "Suppression of Acute Experimental Colitis by a Highly Selective Inducible Nitric-Oxide Synthase Inhibitor, N-[3-(Aminomethyl)benzyl]acetamidine", <u>The Journal of Pharmacology and Experimental Therapeutics</u> , Vol. 298, No. 3, Pgs. 1128-1132, (2001).
A15	Liu, Z-Q, et al., "Specificity of inducible nitric-oxide synthase inhibitors: prospects for their clinical therapy", <u>Acta Pharmacol Sin</u> , Vol. 20, No. 11, Pgs. 1052-1056, (1999).
A16	Salvemini, D., et al., "Dual Inhibition of Nitric Oxide and Prostaglandin Production Contributes to the Antiinflammatory Properties of Nitric Oxide Synthase Inhibitors", <u>J. Clin. Invest.</u> , Vol. 96, Pgs. 301-308, (1995).
A17	Cuzzocrea, S., et al., "Beneficial effects of GW274150, a novel, potent and selective inhibitor of INOA activity, in a rodent model of collagen-induced arthritis", <u>European Journal of Pharmacology</u> , Vol. 453, Pgs. 119-129, (2002).

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP'609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.